Early clinical data point to extended survival and the rare possibility of complete remission in metastatic pancreatic cancer, a malignancy notoriously difficult to treat due to limited therapeutic options. As global drugmakers race to develop effective treatments for refractory cancers, South Korean biotech firm Onconic Therapeutics has reported notable clinical responses for its dual-target anticancer candidate, Nesuparib, in studies evaluating real-world patients.
Onconic Therapeutics announced that initial findings from the Phase 1b portion of its ongoing Phase 1b/2 clinical trial for Nesuparib (also known as JPI-547) have been published in an abstract ahead of the American Society of Clinical Oncology (ASCO 2026) annual meeting. This marks the first time the company has publicly disclosed clinical efficacy data for the drug candidate in human subjects.
The trial evaluated Nesuparib as a first-line treatment in 27 patients with locally advanced or metastatic pancreatic cancer. The study design combined the oral candidate with one of two established standard-of-care regimens: either modified FOLFIRINOX (mFOLFIRINOX) or the combination of gemcitabine and nab-paclitaxel, commonly known as GemAbraxane. The data analyzed in the abstract were collected through a cutoff date of December 31, 2025.
A Dual-Target Mechanism Leveraging Synthetic Lethality
Nesuparib is designed as a next-generation dual-target therapeutic that simultaneously blocks poly(ADP-ribose) polymerase (PARP) and tankyrase. This approach leverages a biological strategy known as synthetic lethality, which selectively destroys cancer cells by blocking their secondary DNA repair pathways when they already possess underlying genetic vulnerabilities.
By targeting these pathways, blocking a key repair enzyme like PARP forces cells to rely on alternative repair mechanisms; when those secondary pathways are also compromised or inhibited, the accumulation of DNA double-strand breaks causes tumor-selective cell death while sparing normal cells. Beyond blocking DNA repair, Nesuparib's inhibition of tankyrase is intended to disrupt the signaling pathways that govern tumor growth and metastasis, creating a multi-pronged assault on aggressive cancer cells.
Striking Efficacy Observed in Standard-Therapy Combinations
The most pronounced clinical responses emerged from the GemAbraxane combination arm of the study. In this group, the objective response rate reached 53.8%, while the disease control rate was recorded at 92.3%. The objective response rate measures the percentage of patients experiencing a predefined reduction in tumor size, whereas the disease control rate additionally counts those whose disease remains stable without progression.
Significantly, one patient with metastatic pancreatic cancer in the GemAbraxane arm achieved a complete response, meaning all tracked cancer cells in the target lesions disappeared entirely on imaging scans. This patient has achieved long-term survival, with an overall survival period now exceeding three years. Because pancreatic cancer is typically diagnosed at an advanced stage and carries an exceptionally poor prognosis, cases of complete remission remain exceedingly rare in clinical practice.
Survival metrics from the trial also yielded encouraging signals. While the median overall survival for the GemAbraxane combination group was calculated at 14.2 months, the data remain immature, and extended patient follow-up is still underway. The median progression-free survival for this cohort had not yet been reached at the time of the analysis.
The mFOLFIRINOX combination arm demonstrated robust antitumor activity as well, posting an objective response rate of 38.5% and an identical disease control rate of 92.3%. For patients in this group, the median progression-free survival was 7.33 months, and the median overall survival reached 18.5 months. Achieving a disease control rate above 90% across both treatment arms is considered a highly meaningful clinical signal in a patient population that has historically been resistant to conventional management.
Next Steps in Global Clinical Development
These early results present a favorable contrast to historical data for existing standard monotherapies. For context, the benchmark global MPACT trial, which established the standard gemcitabine monotherapy regimen for metastatic pancreatic cancer, previously reported an objective response rate of 23%, a disease control rate of 48%, and a median overall survival of approximately 8.5 months. However, oncology experts caution that because these new Nesuparib data originate from a small, early-stage cohort, larger comparative trials are necessary to fully confirm definitive efficacy and long-term safety profiles.
Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, previously confirmed in preclinical models that Nesuparib possesses the capacity to suppress drug resistance and hinder tumor metastasis. The clinical findings presented for ASCO 2026 represent a critical step toward validating whether these laboratory mechanisms successfully translate into therapeutic benefits for patients.
The clinical development of Nesuparib extends beyond pancreatic malignancies. The drug candidate has already secured Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for three distinct indications: pancreatic cancer, gastric and gastroesophageal junction cancer, and small cell lung cancer.
Based on the safety and preliminary efficacy established in the Phase 1b portion, Onconic Therapeutics has initiated Phase 2 clinical trials evaluating the GemAbraxane and Nesuparib combination. Company officials stated that the combination data and the over three-year survival benchmark justify aggressive development, adding that they anticipate these results will bolster ongoing discussions regarding global licensing partnerships and co-development opportunities with international pharmaceutical firms.
